Advertisement
Screener

Perrigo Company plc (PRGO) Increase (Decrease) in Other Noncurrent Liabilities

2.8 / 5 stars · 68/120 Roast Me

Perrigo Company plc Increase (Decrease) in Other Noncurrent Liabilities

Perrigo Company plc (PRGO) reported Increase (Decrease) in Other Noncurrent Liabilities of $2.60 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-05

  • Perrigo Company plc increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-27 was -$100.00K, a 103.45% decline year-over-year.
  • Perrigo Company plc increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-28 was $2.70M.
  • Perrigo Company plc increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$11.50M.
  • Perrigo Company plc increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-27 was $8.90M.
  • Perrigo Company plc increase (decrease) in other noncurrent liabilities for fiscal 2025 was -$200.00K.
  • Perrigo Company plc increase (decrease) in other noncurrent liabilities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
  • Perrigo Company plc increase (decrease) in other noncurrent liabilities for fiscal 2023 was $7.60M.
Period endIncrease (Decrease) in Other Noncurrent Liabilities 3 monthIncrease (Decrease) in Other Noncurrent Liabilities 6 monthIncrease (Decrease) in Other Noncurrent Liabilities 9 monthIncrease (Decrease) in Other Noncurrent Liabilities 12 month
2026-06-27-$100.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$2.60M
10-Q · filed 2026-08-05
-$8.90M
derived: sum of 3 quarters · filed 2026-08-05
$0.00
derived: sum of 4 quarters · filed 2026-08-05
2026-03-28$2.70M
10-Q · filed 2026-05-06
-$8.80M
derived: sum of 2 quarters · filed 2026-05-06
$100.00K
derived: sum of 3 quarters · filed 2026-05-06
$3.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$11.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$2.60M
derived: sum of 2 quarters · filed 2026-02-26
$300.00K
derived: sum of 3 quarters · filed 2026-08-05
-$200.00K
10-K · filed 2026-02-26
2025-09-27$8.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$11.80M
derived: sum of 2 quarters · filed 2026-08-05
$11.30M
10-Q · filed 2025-11-05
-$3.60M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-28$2.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$2.40M
10-Q · filed 2026-08-05
-$12.50M
derived: sum of 3 quarters · filed 2026-08-05
2025-03-29-$500.00K
10-Q · filed 2026-05-06
-$15.40M
derived: sum of 2 quarters · filed 2026-05-06
2024-12-31-$14.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$0.00
10-K · filed 2026-02-26
2024-09-28$14.90M
10-Q · filed 2025-11-05
2023-12-31$7.60M
10-K · filed 2026-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Generate Biomedicines, Inc. (GENB)United States$2.052B
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38